908.1500 -2.25 (-0.25%)
NSE Oct 06, 2025 15:06 PM
Volume: 51,326
 

908.15
-0.25%
HDFC Securities
Incremental revenues from the front-end in the US, and a sequential uptick in gAbilify sales led to 25% YoY revenue growth in 1QFY17. EBITDA at Rs 1.5bn was up 55% YoY and margins improved to 21.3% ( 423bps). Driven by strong operating performance, PAT grew 48% YoY to Rs 1bn.
Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.
More from Alembic Pharmaceuticals Ltd.
Recommended